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The vgf gene (non-acronymic) is highly conserved and was identified on the basis of its
rapid induction in vitro by nerve growth factor, although can also be induced by brain-
derived neurotrophic factor, and glial-derived growth factor. The VGF gene gives rise to a
68 kDa precursor polypeptide, which is induced robustly, relatively selectively and is syn-
thesized exclusively in neuronal and neuroendocrine cells. Post-translational processing by
neuroendocrine specific prohormone convertases in these cells results in the production of
a number of smaller peptides.TheVGF gene and peptides are widely expressed throughout
the brain, particularly in the hypothalamus and hippocampus, in peripheral tissues including
the pituitary gland, the adrenal glands, and the pancreas, and in the gastrointestinal tract in
both the myenteric plexus and in endocrine cells. VGF peptides have been associated with
a number of neuroendocrine roles, and in this review, we aim to describe these roles to
highlight the importance ofVGF as therapeutic target for a number of disorders, particularly
those associated with energy metabolism, pain, reproduction, and cognition.
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INTRODUCTION
VGF (non-acronymic) is a neurotrophin-induced gene, which was
first identified as VGF8a, NGF33.1, and a2 on the basis of its
rapid induction in PC12 cells treated with nerve growth fac-
tor (NGF) (1–3). Subsequent studies demonstrated that VGF
is similarly upregulated by numerous neurotrophins, including
brain-derived neurotrophic factor (BDNF) and neurotrophin-3
(NT-3), in neuronal targets such as cortical or hippocampal neu-
rons (4). However,VGF mRNA levels are only marginally increased
by other growth factors including epidermal growth factor (EGF),
fibroblast growth factor (FGF), interleukin-6 (IL-6), and insulin,
despite the capacity of these proteins to robustly induce tran-
scription of other immediate early genes in the PC12 cell line
(3, 5, 6).
The VGF polypeptide, which is robustly and exclusively synthe-
sized in neuronal and neuroendocrine cells (1, 3, 7, 8), is processed
by the prohormone convertases (PC), PC1/3 and PC2 (9). VGF
derived peptides with specific neuronal bioactivities include
TLQP-62, TLQP-21, HHPD-41, AQEE-30, AQEE-11, LQEQ-19,
and neuroendocrine regulatory peptides-1 and -2 (NERP-1 and -
2; 9–11). Studies have shown that TLQP-62 and AQEE-30 increase
the firing rate of hippocampal neurons, induce neurogenesis, and
have anti-depressive properties (4, 12, 13), whereas HHPD-41,
AQEE-30, AQEE-11, and LQEQ-19 stimulate sympathetic outflow
and facilitate penile erection in rats (14–16); and TLQP-21 and
NERP-2 regulate energy balance (17–20). Furthermore, TLQP-21
regulates contractile activity in the gastrointestinal tract, has anal-
gesic properties, reduces neuronal apoptosis in vitro and decreases
rodent blood pressure (21–23) and NERP-1 and -2 regulate water
homeostasis and suppress vasopressin release (11, 20, 24). Here,
we review the regulation of VGF and the neuroendocrine role of
its derived peptides.
THE TRANSCRIPTIONAL REGULATION OF VGF
IN VITRO
The gene itself is highly conserved among mammalian species in
respect to the coding region and the promoter sequence (25). The
VGF promoter region contains a CCAAT box, various specificity
protein 1 (SP-1), and activating protein 2 (AP-2) sites and a silencer
element similar to the one involved in tissue-specific expression
of neuronal genes (3, 25). Furthermore, it contains a cyclic AMP
response element (CRE), which is embedded within a 14bp palin-
dromic sequence, mutations of which abolish NGF and cAMP
responses (6). VGF expression in response to neurotrophins that
requires the combined actions of several regulator complexes; in
addition to the CRE, the CCAAT box was shown to be important
for NGF induction (26), possibly in association with the activ-
ity of a large complex containing a CRE binding protein (CREB),
mammalian achaete-scute homolog-1 (MASH-1), and p300 (27).
IN VIVO
A genomic fragment extending from 800-bp 5’ to the transcrip-
tional start site and including the first 700-bp of 5’-untranslated
sequence results in reporter gene expression in a tissue-restricted
pattern similar to that of the endogenous VGF gene (28). Inter-
estingly, this region of the promoter contains a putative silencer
element that is located 400-bp 5’ to the transcriptional start site,
which prevents expression in non-neuronal cell lines (25). VGF
mRNA in the hypothalamus alters in response to feeding/fasting
(14, 15, 20), salt loading (29), adrenalectomy (30), and seasonal
rhythms (31). Furthermore, VGF mRNA varies in the pituitary
during the estrous cycle (32) and in the suprachiasmatic nucleus
(SCN) according to circadian rhythmicity (33); while gastric dam-
age increases VGF mRNA in the nucleus tractus solitarius (NTS)
and dorsomedial nucleus of the vagus (34). VGF mRNA is also
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modulated in other diverse conditions, which have been well
described elsewhere (35).
THE STRUCTURE AND PROCESSING OF THE VGF
POLYPEPTIDE
VGF is a 68 kDa polypeptide comprising 615 (human) or 617
(mouse/rat) amino acids with a typical secretory leader sequence
of 22 amino acids at the N-terminal of VGF, which promotes
translocation to the endoplasmic reticulum (ER) (36). Subsequent
sequencing of the polypeptide in the mouse, horse, and bovine has
confirmed extensive sequence conservation with approximately
>85% identity (35). The most prominent VGF-derived peptides
have apparent molecular masses of 20 (NAPP-129) and 10 kDa
(TLQP-62), respectively (9) (Figure 1). However, the mouse and
human sequences contain a minimum of 10 conserved regions
of basic amino acid residues, which represent potential PC cleav-
age sites (37) (Figure 2). Indeed cleavage at the Arg-Pro-Arg555
sequence in the rat has been shown to give rise to the TLQP pep-
tides (9). It is possible, however, that the number and function of
VGF derived peptides are greater than currently known (38). The
extensive review by Ferri et al. (35) describes this in more detail.
DISTRIBUTION OF VGF AND ITS DERIVED PEPTIDES
VGF mRNA
VGF mRNA is widely expressed throughout the nervous sys-
tem. During embryogenesis VGF mRNA is expressed in distinct
neurotrophin-responsive targets in the central and peripheral ner-
vous system (CNS and PNS, respectively) in the rat (39, 40). At
birth, VGF mRNA is expressed in neurons throughout the brain
and in peripheral endocrine and neuroendocrine tissues. While
in the adult brain VGF mRNA has the highest expression in the
hypothalamus and the granular layer of the cerebellum, it is also
expressed in a number of other brain areas including the main
and accessory olfactory bulbs, hippocampus, cortex, basal ganglia,
thalamus, amygdala, midbrain, and the brainstem. Within the
hypothalamus, the highest concentrations of VGF mRNA have
been found in the ventromedial hypothalamus, in particular the
arcuate nucleus (ARC), as well as in the SCN (7, 39, 41). VGF
mRNA expression in the mouse is similar to the rat (14).
VGF PEPTIDES
VGF and its derived peptides are found in dense core vesicles and
are released in response to depolarizing signals from neuronal and
neuroendocrine cells through the regulated secretory pathway (10,
42, 43). Antibodies raised to synthetic peptides corresponding to
the C- or N-termini of potential or actual cleavage products have
been utilized to study VGF derived peptide distribution. In ani-
mal tissues, VGF immunoreactivity was restricted to central and
peripheral neurons (41, 44), as well as to endocrine cells of the
pituitary, adrenal medulla, gut, and pancreas (44). The highest
concentrations of VGF immunoreactivity have correspondingly
been found in the medial hypothalamus, particularly in the ARC,
in the SCN, and in the parvocellular and magnocellular cells of
the paraventricular nucleus (PVN) and the supraoptic nucleus
(SON) (41). Weak immunoreactivity was also detected in the hip-
pocampus, amygdala, thalamus, and cerebral cortex (41). VGF
immunoreactivity was also displayed in the female rat in the pars
distalis, mainly with C-terminal antibodies (32). This, however,
disappeared in accordance with the estrous peak of luteinizing
hormone (LH) secretion, along with an induction of VGF mRNA
in the pituitary. Additionally,VGF-derived peptides are prominent
in the adult spinal cord, in α- and γ-motor neurons of the ventral
horn and in the dorsal horn neurons, as well as cells of the inner
nuclear and ganglion cell layers of the retina (45). In the PNS,
both sympathetic ganglia and dorsal root ganglia of primary sen-
sory neurons are important sites of localization of VGF-derived
FIGURE 1 |The vgf gene and its derived peptides. The VGF
polypeptide is the precursor of several biologically active peptides,
which are released and play a role in intercellular communication.
The gene contains a number of specific sequences, which are
highly conserved between the species and these represent
potential cleavage sites for the convertases of the kexin/subtilisin-like
series proteinases family, namely prohormone convertases-1/3
and -2.
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FIGURE 2 | Comparison of the human and mouseVGF polypeptide
sequences. * indicates the position which have a single, fully conserved
residue. “:” indicates conservation between groups of strongly similar
properties scoring >0.5 in the Gonnect PAM 250 matrix. “ . ” indicates
conservation between groups of weakly similar properties scoring
<0.5 in the Gonnect PAM 250 matrix. Clusters of basic amino acids,
which represent potential cleavage sites, are boxed. Sequence identity
was >85%.
peptides (40). This is comparable to the expression of neuropep-
tide Y (NPY), ghrelin, and cholecystokinin (CCK), all of which
regulate feeding and in some cases, gastrointestinal motility (46,
47). VGF-derived peptides are also present in mouse brown adi-
pose tissue (BAT), where they are reduced in response to a high fat
diet (HFD) (48).
VGF RECEPTORS
Of all the VGF derived peptides, TLQP-21 has had the most inter-
est (17, 19, 23, 49–52). Previously, TLQP-21 was shown to bind to
adipocyte membranes in a saturable manner, (53) and atomic force
microscopy of living cells revealed the existence of a single class of
binding sites for TLQP-21 (54). Taken together these results sug-
gested a cell surface receptor for TLQP-21. Two possible receptors
have recently been identified for TLQP-21. Chen et al. (55) iden-
tified gC1qR, showing that TLQP-21 activated rat macrophages
through gC1qR, which then caused mechanical hypersensitivity
in rats. gC1qR protein was expressed by both brain and spinal
cord derived microglia (55) and is indispensable for adipogenesis
and insulin signaling (56). Furthermore, obese mice fed a HFD
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demonstrated increased density of TLQP-21 binding in adipose
tissues (54). However, neither TLQP-62 nor LQEQ-19 elicited a
response in their experimental model, both of which had been
previously implicated in pain processing (22, 57). This supports
the hypothesis of different receptors for the VGF derived peptides.
Hannedouche et al. (58) reported the complement receptor, C3A
receptor-1 (C3AR1), as a receptor for TLQP-21, which mediated
activity for TLQP-21 in two different rodent cell lines. C3AR1 was
originally thought to be restricted to the innate immune response,
its role limited to the complement cascade. However, it has sub-
sequently been shown to have a role in cancer (59), neurogenesis
(60), and hormone release from the pituitary gland (61). However,
C3AR1-/- mice are transiently resistant to diet-induced obesity
(DIO) and are protected against HFD-induced insulin resistance
(62). The discovery of these receptors will help identify the mech-
anisms by which TLQP-21 and possible other derived peptide may
modulate its actions.
PHYSIOLOGICAL ROLES OF VGF GENE AND DERIVED
PEPTIDES
ENERGY BALANCE
The high expression of VGF in the hypothalamus and the change
in expression of the vgf gene in the ARC following acute altered
energy balance first suggested the importance of VGF in the regu-
lation of energy balance (14, 20). Indeed fasting has been shown
to increase VGF mRNA expression, while administration of leptin
prevents the fasting induced increase in VGF mRNA (15). These
changes in VGF can be observed in models of chronic energy
imbalance; VGF mRNA levels resemble that of fasted wild-type
mice in the ARC of the leptin deficient ob/ob mouse and in the lep-
tin resistance db/db mouse (15). It is well known that the ARC has
two neuronal populations that respond to the fed and fasted state
as well as to leptin signaling, the pro-opiomelanocortin (POMC)
and neuropeptide Y (NPY) neurons (63). VGF immunoreactivity
has been shown to be co-localized with both these neuronal popu-
lations in the ARC, however, expression is modulated with energy
state. In the ad libitum fed state and re-fed animals, VGF mRNA
is co-localized with POMC (15, 64). On the other hand, fasting
increases co-localization of VGF in the NPY neurons (64).
Energy balance and lack of functional VGF
The function of VGF and its extension derived peptides was first
assessed through the development of mice lacking a functional
copy of the vgf gene (VGF-/-) via homologous recombination (14).
At birth, the homozygous VGF-/- mice are indistinguishable from
either their heterozygous or wild-type littermates. No defects in
development were detected in either the CNS or the PNS. How-
ever, in the weeks following birth, the VGF-/- mice were visibly
smaller than their wild-type littermates and adults were found
to weigh 50-70% less due to a 50% reduction in adiposity com-
pared to wild-type littermates (14). Consistent with the reduction
in adiposity, leptin levels, serum glucose and insulin levels, and
liver glycogen were reduced (48). The mice consumed consider-
ably more calories per gram body weight, but this increase in food
intake was not sufficient to maintain the same body weight as wild-
type mice. The VGF-/- mice utilized twice as much oxygen at rest
and displayed increased locomotor activity compared to wild-type
littermates (14). Overall, the major change in VGF-/- mice is an
increase in energy consumption; indeed vgf gene deletion did
not block obesity via monosodium glutamate administration (15)
suggesting that the thermogenic pathways resulting in the VGF-/-
phenotype are blocked. These initial observations led Hahm et al.
(14) to suggest that VGF may play a non-redundant role in the
regulation of energy homeostasis and antagonism of the gene
may constitute a basis for the treatment of obesity. Furthermore,
vgf gene deletion blocked the development of obesity as a result
of a HFD, gold thioglucose treatment, as well as in the agouti
mouse, and suggesting that VGF functions in outflow pathways
regulating energy expenditure downstream of the hypothalamic
melanocortin receptors (15).
Energy balance and VGF-derived peptides
Thus from the phenotype of the VGF-/- mice one might predict
that VGF promotes an anabolic drive. Surprisingly, this view has
not been supported by subsequent studies in mice and Siber-
ian hamsters. Chronic intracerebroventricular (ICV) infusion of
TLQP-21 in mice fed a normal lab chow resulted in a small
increase in resting energy expenditure and rectal temperature
(17). The changes in metabolic parameters were mirrored by
increased epinephrine content in BAT, upregulation of BAT β2-
adrenergic receptor (AR), uncoupling protein 1 (UCP-1) mRNA,
higher expression of peroxisome proliferator-activated receptor-
δ (PPAR-δ), and β3-AR in white adipose tissue (WAT). How-
ever, hypothalamic expressions of agouti-related protein (AgRP),
NPY, α-melanocyte-stimulating hormone (α-MSH), POMC, and
corticotrophin-releasing hormone (CRH) were unchanged (17).
In mice, switched to a HFD treatment with TLQP-21 halted the
expected increase in body weight and WAT, attenuated rises in
leptin, and normalized ghrelin levels (17). In rats, ICV infusion
of TLQP-21 significantly decreased gastric emptying, an effect
that was blocked by ICV infusion of indomethacin, which blocks
prostaglandin release (65).
A similar catabolic effect was noted in Siberian hamsters, a
seasonal model of energy balance. Not only is VGF mRNA sig-
nificantly increased in the winter weight-loss state in the dorsal
medial posterior arcuate nucleus (dmpArc) (31) but ICV infusion
of TLQP-21 at the onset of the dark phase was found to signifi-
cantly and dose dependently decrease food intake and body weight
(19). However, there was no effect on energy expenditure as Siber-
ian hamsters pair-fed to the treated group lost a similar amount
of body weight (19). Weight loss was, therefore, attributable to
reduced caloric intake rather than energy expenditure.
One of the possible explanations for this contradiction between
the functional in vivo studies and the VGF-/- mice, where all the
VGF peptides have been ablated, is that some of these peptides
may have opposing roles in energy balance. Interestingly, Bartolo-
mucci et al. (66) have suggested that HHPD-41 increased food
intake following ICV infusion, and more recently ICV infusion
of NERP-2 in rats has been shown to increase food intake, body
temperature, oxygen consumption, and locomotor activity (20).
Furthermore, intravenous administration of NERP-2 significantly
augmented glucose stimulated insulin secretion in anesthetized
rats or following intraperitoneal injection to conscious mice (67).
Thus VGF may have a biphasic role in the regulation of energy
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balance and further characterization of the other VGF-derived
peptides is required.
Energy balance and circadian rhythm
It is well known that food intake and energy metabolism in mam-
mals are regulated by their circadian clock, and food intake is one
such signal that can entrain the circadian clock (68). As previously
described, VGF is expressed in the SCN, the circadian pacemaker
in animals, while the E-box contained in the vgf gene promoter
region is similar to the many clock genes such as the per gene (33).
Therefore, it is not unexpected that the vgf gene exhibits circadian
rhythm in the SCN even under constant dark conditions, while
VGF mRNA levels are increased in response to light simulation in
the SCN when light would be expected to cause a phase shift in
locomotor rhythms (33). Indeed VGF-/- mice can maintain circa-
dian rhythm of wheel running in constant darkness, however, the
period length was found to be slightly but significantly shorter than
wild-type littermates (14). Thus, this raises the question could the
metabolic phenotype of the VGF-/- mice be attributed, in part, to
the disruption of the circadian system.
VGF ANDWATER BALANCE
Water deprivation and salt loading in rats increases VGF mRNA
levels in both the SON and PVN, along with vasopressin mRNA
(29). ICV injection of NERP-1 and NERP-2 suppresses hypertonic
saline or angiotensin II induced increases in plasma vasopressin
in rats (69). Additionally, ICV infusion of NERP-1 and -2 atten-
uated the increase in vasopressin as a result of water deprivation
in rats, an effect which was reversed following immunoneutralisa-
tion by ICV infusion of anti-NERP-1 and -2 antibodies (69). Taken
together, these data suggest that NERP-1 and -2 may be involved
in the central control of body fluid balance.
VGF AND REPRODUCTION
The role of VGF signaling in reproduction was inferred from the
observation that VGF gene deletion resulted in infertility in both
male and female mice (14). In male VGF-/- mice, the onset of
puberty and sexual maturation was delayed, and the weights of the
testes, albeit having mobile spermatozoa in the lumen, were signif-
icantly lower than those of wild-type littermates (14). While in the
female VGF-/- mice histological examination revealed no mature
follicles or corpus lutea, and the ovaries, ovidut, and uteri weighed
30% less than those of the wild-type littermates (14). However,
transplanting ovaries from VGF-/- mice into ovariectomized wild-
type females restored fertility, suggesting that the reproductive
deficits of VGF-/- mice were not the result of pathology but arose
from deficits in the hypothalamic-pituitary-gonadal axis (14).
However, Ferri et al. (32) showed that VGF gene expression varied
during estrous; there was an increase in VGF mRNA and VGF pep-
tide/s degranulation, suggesting perturbation of anterior pituitary
function.
It is common knowledge that alterations in energy metabo-
lism and fat stores can affect reproductive function. VGF-/- mice
have reduced leptin and altered energy status, therefore, it could
be suggested that the deficit may be due to gonadotropin releas-
ing hormone (GnRH) synthesis or secretion. However, while
GnRH levels are not affected, LH and follicle-stimulating hormone
(FSH) mRNA levels were reduced in VGF-/- mice (14) suggesting
decreased GnRH secretion. Indeed it has been shown that cen-
tral administration of TLQP-21 in female rats during the pubertal
transition advanced the timing of vaginal opening and increased
the number of animals with signs of ovulation (70). These effects
of TLQP-21 may be via stimulation of the GnRH release, as
TLQP-21 has been shown to induce LH secretion in vitro (71).
Furthermore, Pinilla et al. (71) have shown that chronic admin-
istration of TLQP-21 was able to prevent the hypogonadotropic
state induced by food deprivation.
There is further evidence of VGF peptides and a possible role
in the regulation of reproduction. While HHPD-41, AQEE-30,
and LQEQ-19 have been shown to induce penile erection in rats
following infusion into the PVN in a dose dependent manner,
NERP-1 has a pro-erectile effect when injected into the lateral
ventricles or the ARC of rats (72). The effect on penile erection is
thought to be via nitric oxide mediated activation of oxytocinergic
pathways (16).
VGF AND PAIN
VGF is a gene commonly upregulated in sensory neurons in
clinically relevant models of neuropathic pain, namely, varicella
zoster infection, HIV-associated neuropathy, and peripheral nerve
trauma (55). Furthermore, VGF has been shown to be upreg-
ulated in the dorsal root ganglia and spinal cord in a number
of neuropathic and inflammatory pain models (22, 57, 73–76).
In these areas, VGF is co-localized with substance P, calcitonin
gene related peptide, TrkA, and P2× 3 (22, 51). A functional role
for VGF-derived peptides has been identified in pain pathways.
Indeed intrathecal infusion of TLQP-62 results in cold behav-
ioral hypersensitivity in rats; while injection of TLQP-21 into the
hind paw of mice resulted in hypersensitivity in both control ani-
mals and the formalin model of inflammatory pain (51) as well as
inducing thermal hyperalgesia in the warm-water immersion tail-
withdrawal test (77). Additionally, both LQEQ-19 and AQEE-30
have been shown to induce p38 MAP kinase phosphorylation in
spinal microglia (22), suggesting that VGF-derived peptides have
pro-nociceptive and hyperalgesic functions.
VGF AND MEMORY AND LEARNING
As previously stated VGF mRNA is expressed in the hippocam-
pus, and it has been shown that VGF transcription is accompanied
by translation within 3 hours of BDNF exposure in hippocampal
slices in vitro (4). Additionally, VGF mRNA has been shown to
be upregulated by activities, such as memory and learning (8),
while VGF-/- mice have demonstrated impaired hippocampal-
dependent spatial learning and contextual fear conditioning tasks
(78). Indeed more recently, TLQP-62 has been shown to induce
transient potentiation in hippocampal slices (78), enhance synap-
tic activity (4), and increase neurogenesis in early phase neural
progenitor cells in the adult hippocampus (12,79), as well as shown
to have effect on cognitive mechanism (80), thus suggesting that
VGF may be important in memory processes.
To further support this notion, proteomic studies have demon-
strated a reduction in VGF-derived peptides in the cerebrospinal
fluid of patients affected by Alzheimer’s disease (AD) (81–83).
Similarly, there was a reduction in VGF-derived peptides in the
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parietal cortex of AD patients (84) and a reduction in TPGH and
NERP-1 in the parietal cortex of Parkinson’s disease patients (84).
VGF AND DEPRESSION
VGF protein expression is reduced in both the learned helpless-
ness and forced swim test depression paradigms (85), while VGF
is increased by antidepressant drugs and voluntary exercise (12).
Exercise regulatesVGF mRNA and protein expression in the rodent
hippocampus and induces an antidepressant response; an oppos-
ing phenotype is observed in the heterozygous VGF-/+mouse (86).
Recently, inhibition of phosphodiesterase-4 or -5 was shown to
result in increases in cAMP, activating CREB, BDNF, and VGF,
which produces antidepressant-like effects on behavior in mice
(87). Similarly, microinjection of TLQP-62 into the hippocampal
CA1 regions demonstrated antidepressant-like behavioral effects
in mice (88), possibly via a BDNF-dependent mechanism (78).
CONCLUSION
The evidence presented in this review indicates that the gene and
gene product have a key neuroendocrine role and that VGF or its
derived peptides may act as biomarkers or therapeutic targets in
a number of disorders such as obesity, dementia, depression, and
pain. The mechanisms by which VGF and its derived peptides are
involved remains to be identified, however, the discovery of the
new receptors will help advancements in this area both in vitro
and in vivo.
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